title: Wells' syndrome associated with chronic myeloid leukaemia.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nakazato
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Fujita
authors.forename: Yohei
authors.initials: Y
authors.lastname: Hamade
authors.forename: Ikue
authors.initials: I
authors.lastname: Nemoto-Hasebe
authors.forename: Junichi
authors.initials: J
authors.lastname: Sugita
authors.forename: Wataru
authors.initials: W
authors.lastname: Nishie
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shimizu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001706:Biopsy; D002481:Cellulitis / Q000150:complications* / Q000473:pathology; D004802:Eosinophilia / Q000150:complications* / Q000473:pathology; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib